TKPHF TAKEDA PHARMACEUTICAL CO LTD
Price Chart
Executive Summary
Takeda reported FY2025 (year ended March 31, 2026) results showing a net loss attributable to owners of JPY 152.4 billion, swinging from a profit of JPY 107.9 billion in FY2024, driven primarily by a JPY 403.5 billion provision for the AMITIZA antitrust litigation jury verdict. Core operating profit rose 0.8% to JPY 1,172.5 billion, but FY2026 guidance calls for core operating profit to decline 1.1% and core EPS to fall 8.7%, with management guidance at CER pointing to a 5-8% decline in core operating profit and mid-teens decline in core EPS.
Actionable Insight
The AMITIZA antitrust verdict creates material legal overhang — the jury awarded USD 884.9 million in single damages, with automatic trebling for wholesaler and retailer classes. Takeda intends to appeal, but the district court judgment expected in H2 2026 is a key catalyst. Core operating profit guidance for FY2026 implies continued margin pressure from generic erosion and transformation costs. Monitor the appeal outcome and any settlement developments.
Key Facts
- Revenue declined 1.7% YoY to JPY 4,505.7 billion (CER -2.7%), driven by a 26.8% drop in Neuroscience revenue from VYVANSE generic erosion.
- Reported net loss attributable to owners was JPY 152.4 billion vs. profit of JPY 107.9 billion in FY2024, due to a JPY 403.5 billion provision for the AMITIZA antitrust litigation.
- Core operating profit was JPY 1,172.5 billion, up 0.8% YoY (CER -0.9%), with core EPS of JPY 517, up 5.2%.
- FY2026 guidance: revenue growth of 3.0% to JPY 4,640.0 billion, but core operating profit expected to decline 1.1% to JPY 1,160.0 billion and core EPS to fall 8.7% to JPY 472.
- Management guidance at CER: low-single-digit % decline in core revenue, 5-8% decline in core operating profit, and mid-teens % decline in core EPS.
- Adjusted net debt to adjusted EBITDA ratio improved to 2.6x from 2.8x in FY2024.
- Dividend increased to JPY 200 per share for FY2025, with FY2026 guidance of JPY 204 per share.
Financial Impact
Reported net loss of JPY 152.4 billion vs. profit of JPY 107.9 billion; core operating profit up 0.8% but FY2026 core EPS guidance down 8.7%.
Risk Factors
- AMITIZA antitrust litigation: potential treble damages and final judgment could significantly exceed the JPY 403.5 billion provision.
- Continued generic erosion of VYVANSE in the U.S. weighing on Neuroscience revenue.
- FY2026 core EPS guidance of JPY 472 implies an 8.7% decline, with management guidance at CER pointing to mid-teens decline.
- Transformation program restructuring expenses expected to increase to JPY 170.0 billion in FY2026 from JPY 70.8 billion in FY2025.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000166 |
| Exhibit: exhibit991.htm | 0001395064-26-000166 |
| Document: 0001395064-26-000166-index-headers.html | 0001395064-26-000166 |
| Document: 0001395064-26-000166-index.html | 0001395064-26-000166 |
| Document: 0001395064-26-000166.txt | 0001395064-26-000166 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
3d ago
|
6-K
| $31.30 awaiting T+5 | awaiting T+5 | — | $34.28 (+9.52%) |
|
Jun 5, 2026
7d ago
|
6-K
| $30.47 awaiting T+5 | awaiting T+5 | — | $34.28 (−12.50%) |
|
Jun 5, 2026
7d ago
|
6-K
| $30.47 awaiting T+5 | awaiting T+5 | — | $34.28 (−12.50%) |
|
Jun 1, 2026
11d ago
|
6-K
| $30.47 $30.47 | · 0.00% | ▲ +2.75% | $34.28 (+12.50%) |
|
May 26, 2026
17d ago
|
6-K
| $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $34.28 (+6.79%) |
|
May 26, 2026
17d ago
|
6-K
| $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $34.28 (+6.79%) |
|
May 26, 2026
17d ago
|
6-K
| $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $34.28 (+6.79%) |
|
May 26, 2026
17d ago
|
6-K
| $32.10 $30.47 | ▲ +5.08% | ▲ +6.29% | $34.28 (−6.79%) |
|
May 19, 2026
24d ago
|
6-K
| $32.26 $32.10 | ▲ +0.50% | ▲ +2.79% | $34.28 (−6.26%) |
|
May 13, 2026
4w ago
|
6-K
| $32.68 $32.26 | ▼ −1.29% | ▼ −0.13% | $34.28 (+4.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access